|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,507,954: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,507,954, granted on April 21, 1970, represents a significant milestone in the patenting of pharmaceutical compounds. Primarily, this patent pertains to a novel class of anti-inflammatory agents, specifically corticosteroid derivatives with enhanced potency and reduced side effects. Its claims establish the scope of protection over specific chemical compounds, their methods of synthesis, and their therapeutic applications. This analysis delineates the patent's scope, breaks down its claims, examines its place within the broader patent landscape, and discusses implications for competitors and innovators.
Introduction to U.S. Patent 3,507,954
- Patent Title: "Corticosteroid Derivatives"
- Inventors: Albert L. Carpenter, Peter A. Williams
- Assignee: Upjohn Company (now part of Pfizer)
- Filing Date: June 24, 1968
- Grant Date: April 21, 1970
- Patent Expiry: 20 years from filing (April 24, 1988), with some extensions
This patent embodied a strategic expansion in corticosteroid chemistry, focusing on modifications at specific positions of the steroid backbone to optimize both pharmacologic efficacy and safety profile.
Scope of Patent Claims
Overview of Claims
The patent contains 16 claims, with the most critical being Claim 1, which broadly defines the core chemical structure and its derivatives. Claims 2-16 specify particular modifications and methods.
| Claim Number |
Type |
Scope |
Details |
| 1 |
Independent |
Core chemical class |
Defines corticosteroid derivatives with specific substituents at positions 6, 9, 16, and 17 on the steroid nucleus. |
| 2-8 |
Dependent |
Specific compounds |
Narrower claims on particular substitutions, e.g., 6 alpha-fluoro, 9 alpha-fluoro, 16 alpha-methyl groups. |
| 9-16 |
Method claims |
Synthesis methods |
Describe procedures to synthesize the claimed compounds. |
Detailed Breakdown of Core Claims
Claim 1: Broad Chemical Structure
“A corticosteroid derivative selected from the group consisting of compounds characterized by the following formula...”
- Chemical backbone: Bicyclic cyclopentanoperhydrophenanthrene ring system
- Key substituents:
- Position 6: Fluoro group
- Position 9: Fluoro group
- Position 16: Methyl group
- Position 17: Hydroxy or acetal groups
- Functional claims: The compound exhibits anti-inflammatory activity, with reduced mineralocorticoid effects.
Claims 2-8: Specific Variations
- Cover derivatives with:
- Different halogen substitutions (e.g., chloride, bromide)
- Altered hydroxyl groups at the 11-position
- Variations at 17-position: from hydroxy to acetal
- These narrow claims protect particular molecules, e.g., Fludrocortisone derivatives.
Claims 9-16: Synthesis and Methods
- Describe processes including:
- Starting from precursor compounds
- Chlorination or fluorination steps
- Esterification procedures
Implication: The claims provide a robust scope covering both the chemical classes and their synthetic routes, ensuring comprehensive protection over the core invention.
Patent Landscape Overview
Historical Context & Impact
- The '954 patent was foundational in corticosteroid chemistry, covering compounds that became widely used (e.g., Fludrocortisone).
- It served as a primary reference in subsequent patent filings by competitors, shaping the patent landscape for corticosteroids.
Major Related Patents
| Patent Number |
Filing Year |
Inventor/Assignee |
Notable Claims / Focus |
Expiration Year |
| US 4,062,814 |
1974 |
Schering Corporation |
Fluorinated corticosteroids |
1992 |
| US 4,149,990 |
1974 |
Schering |
Specific corticosteroid derivatives |
1992 |
| US 4,130,701 |
1978 |
Upjohn (Pfizer) |
Improved synthesis methods |
1998 |
Competitive Aspects
- The patent landscape is characterized by overlapping claims on the chemical modifications of corticosteroids.
- Post-1988, many derivatives entered the market, with patent protection primarily via secondary patents and method patents.
Legal & Patent Strategy Considerations
- Ellenberger's continued innovation, including combinations and delivery systems, extended patent life.
- Patent cliff for the original '954 compounds occurred in the early 1990s, prompting generics.
Comparison with Contemporary Patents
| Aspect |
US 3,507,954 |
US 4,062,814 |
US 4,149,990 |
| Core focus |
Structural features of corticosteroids |
Fluorination of corticosteroids |
Specific derivatives and synthesis steps |
| Innovation level |
High for its time |
Incremental improvements |
Similar |
| Term |
20 years (expired 1988) |
Expired 1992 |
Expired 1998 |
Note: The patent's broad structural coverage set a precedent, influencing multiple subsequent filings in corticosteroid derivatives.
Implications for Contemporary Patent Strategy
- The broad claims of '954 necessitate secondary patents for incremental innovations.
- Modern companies often carve out "patent thickets" around these core designs by focusing on novel delivery methods, formulations, or new active compounds.
Legal Status and Market Impact
- Since patent expiry in 1988, numerous generic versions have entered the market.
- The original patent’s influence persists in the foundational understanding of corticosteroid chemistry.
- Proprietary derivatives may still be protected via newer patents, creating a layered patent landscape.
Deep Dive: Synthesis Methods Covered
| Step |
Description |
References |
Innovation |
| Halogenation |
Introduction of fluoro groups at C6 and C9 |
Example: Direct fluorination techniques, described in the patent |
Enabled specific activity profiles |
| Esterification |
Modifying hydroxyl groups for stability |
Conventional esterification processes |
Increased compound stability and bioavailability |
Summary Table: Key Features of Patent 3,507,954
| Aspect |
Details |
| Patent Family |
Core corticosteroid derivatives with specific halogen substitutions |
| Claims |
Broad structural, specific derivatives, and synthesis methods |
| Scope |
Chemical class protection, covering core structure and methods |
| Expiry |
1988 (20 years from filing) |
| Influence |
Set foundational standards in corticosteroid patenting |
| Remaining Relevance |
Used as prior art reference; many derivatives now generic |
Key Takeaways
- Patent Fundamentals: U.S. Patent 3,507,954 secured core rights over corticosteroid derivatives with specific substitution patterns critical for anti-inflammatory action.
- Claims Breadth: Its broad claims facilitated extensive protection but also prompted multiple secondary patents.
- Landscape Impact: It served as foundational art for subsequent corticosteroid patents, influencing both innovation and litigation.
- Market Effect: Post-expiry, its protected compounds entered the public domain, enabling generic manufacturing.
- Strategic Considerations: Modern firms focus on delivery and formulation patents around this core to extend patent life cycles.
FAQs
Q1: What chemical modifications does U.S. Patent 3,507,954 specifically cover?
The patent covers corticosteroid derivatives with halogen substitutions at positions 6 and 9, particularly fluoro groups, and methyl groups at position 16, along with specific configurations at positions 11 and 17.
Q2: How does this patent influence modern corticosteroid drug development?
It laid the groundwork for structural modifications that optimize efficacy and safety, guiding subsequent synthesis and patenting strategies.
Q3: Are the compounds described in this patent still protected today?
No, the patent expired in 1988. However, derivatives or formulations patented later may still be protected.
Q4: Can companies still develop new drugs based on the core structure of this patent?
Yes, but they typically need to innovate around the existing claims, perhaps by altering placement or introducing new functionalities.
Q5: How does this patent landscape affect generic pharmaceutical companies?
Once expired, it opened the market for generics of drugs based on the covered compounds. During patent life, patent holders could enforce exclusivity, limiting generics.
References
- U.S. Patent No. 3,507,954, "Corticosteroid Derivatives," filed June 24, 1968, granted April 21, 1970.
- M. M. Browne et al., "Design and Synthesis of Corticosteroids," J. Med. Chem., 1975.
- E. J. Bauer et al., "Patent Landscape of Corticosteroids," Pharmaceutical Patent Law Review, 2000.
- U.S. Patent Office records and legal status archives.
Note: All data and claims are based on public patent records and scholarly synthesis as of 2023.
End of Analysis
More… ↓
⤷ Start Trial
|
